Sequent Scientific expands equity capital, reports Q2 financial results

Sequent Scientific Limited has allotted 1,186,700 fully paid equity shares of ₹2 each to four employees under the SeQuent ESOP 2020. This allotment was approved by the nomination and remuneration committee on November 11, 2025, at an exercise price of ₹86 per equity share. The new shares will rank pari passu with existing equity shares, increasing the company's issued and paid-up equity share capital.

On November 14, 2025, the board of directors approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. These results, including reports from independent auditors, are available for review. The company's unaudited consolidated financial results report total revenue from operations of ₹4,239.90 million for the quarter ended September 30, 2025, and a total comprehensive income of ₹339.50 million for the same period.